Construction and characterization of a Vibrio cholerae serogroup O139 vaccine candidate by genetic engineering

Cancan Cheng, Yanyan Zhou, Biao Kan, Qian Wang, Yongyu RuiMolecular 2014 · DOI

Introduction

Cholera remains a major global health challenge, particularly in regions with inadequate sanitation. While vaccines are available, current options for the O139 serogroup often face issues with cross-protection and "residual virulence"—where live-attenuated strains still cause mild symptoms. This study details the development of NFYY101, a safer, genetically engineered vaccine candidate designed to provide robust immunity without the side effects of traditional attenuated strains.

Genetic Engineering Strategy

The researchers employed a precise two-step strategy using homologous recombination and suicide plasmids to modify the virulent wild-type strain O139-ZJ9693.

First, they performed a "clean sweep" by deleting a massive 39kb chromosomal segment. This region contained the toxin-linked cryptic (TLC) element, the cholera toxin (CTX) genetic element, and the repeats in toxin (RTX) cluster—all major drivers of pathogenicity.

Second, they strategically re-inserted two essential genes: ctxB, which encodes the non-toxic but highly immunogenic B subunit of the cholera toxin, and rstR, which provides immunity against re-infection by wild-type phages. This ensures the vaccine strain remains stable and cannot revert to a virulent state in the environment.

Schematic of the chromosomal engineering process, showing the deletion of virulence clusters and the insertion of protective antigens.

Safety and Expression Results

The resulting strain, NFYY101, was rigorously tested for both its ability to produce protective antigens and its safety profile.

Antigen Expression

Using GM1-ELISA, the team confirmed that NFYY101 expresses the CTB protein at levels comparable to the original virulent strain. This is critical for ensuring the vaccine can effectively "train" the immune system to recognize V. cholerae.

In Vitro and In Vivo Safety

Safety was evaluated using both cellular and animal models. In Hep-2 human epithelial cell cultures, NFYY101 showed no cytotoxic effects, unlike the parent strain which caused characteristic "cell rounding."

The most definitive proof of attenuation came from the rabbit ileal loop model. While the virulent parent strain caused significant fluid accumulation and intestinal congestion, the engineered NFYY101 strain produced no reaction, behaving identically to the negative control.

Rabbit ileal loop test results showing the lack of fluid accumulation in segments treated with the attenuated NFYY101 strain compared to the virulent parent.

Conclusion

The successful construction of NFYY101 represents a significant step toward a safer O139 cholera vaccine. By simultaneously removing multiple virulence factors and "locking" the strain against phage re-infection, the researchers have created a candidate that balances high immunogenicity with an exceptional safety profile. Future work will focus on long-term genetic stability and evaluating the protective immune response in challenge models.

Summary updated

Abstract

The present study aimed to construct and evaluate the live attenuated Vibrio cholerae serogroup O139 vaccine candidate, in which genes encoding protective antigens were integrated into the chromosomal DNA. Using the initial strain, O139-ZJ9693, the toxin-linked cryptic (TLC) and cholera toxin (CTX) genetic elements and repeats in the toxin (RTX) gene cluster were deleted from its chromosomal DNA, and the cholera toxin genes, ctxB and rstR, were transferred into the chromosome to construct the candidate vaccine strain. The expression of ctxB and the vaccine virulence were then examined. Polymerase chain reaction (PCR), enzymatic digestion and electrophoresis were performed to confirm that TLC, CTX and RTX were deleted, and that ctxB and rstR were transferred into the vaccine candidate DNA. According to the preliminary evaluation, the ctxB gene exhibited cholera toxin subunit B expression, and no enterotoxigenic or cytotoxic effects were observed in this strain. In conclusion, a recombinant strain containing genes encoding protective antigens that replaced virulence-associated genes was successfully constructed in the present study; this candidate strain may have the potential to be utilized to further evaluate the immune response.
BibTeX
@inproceedings{cheng2014construction,
  author = {Cancan Cheng and Yanyan Zhou and Biao Kan and Qian Wang and Yongyu Rui},
  title = {{Construction and characterization of a Vibrio cholerae serogroup O139 vaccine candidate by genetic engineering}},
  booktitle = {Molecular},
  year = {2014},
  doi = {10.3892/mmr.2014.2065},
}

Loading related content...

Figure